Precipio Inc Stock Price, News & Analysis

Precipio (NASDAQ: PRPO), a specialty cancer diagnostics company, has scheduled its Q4 and year-end 2024 shareholder update conference call for March 31st, 2025 at 5:00 PM EST. The call will provide updates on all of the company's core businesses.

Shareholders can access the call through:

• Dial-in: 844-695-5519 (US) or 1-412-902-6760 (International)
• Pre-registration link: https://dpregister.com/sreg/10197585/fea81a2627

Investors can submit questions in advance via email to investors@precipiodx.com. A replay will be available approximately 24 hours after the call on Precipio's investor relations website.

Precipio (NASDAQ: PRPO) has achieved two significant financial milestones in Q4-2024, demonstrating progress toward financial independence. The company reported positive Adjusted EBITDA of $0.4M and a cash flow increase of $0.3M (unaudited).

Of the cash flow improvement, $75,000 came from directors' fees paid in stock, with the remainder from operations. The company's pathology service division is now generating sufficient positive cash flow to fund ongoing R&D and investment in the high-value product business.

Management acknowledges potential quarterly fluctuations between positive and negative performance, particularly noting Q1 challenges due to insurance deductible renewals. However, with current cash reserves and growth pipeline, the company believes it's positioned to achieve sustained profitability.

Precipio (NASDAQ: PRPO) announced a significant change in its executive compensation structure, implementing performance-based stock options for senior management. The new options will only vest when the company's 10-day VWAP exceeds $30.30 per share, representing a 5x increase from the exercise price of $6.06. Unlike traditional time-based vesting, these options have no time restrictions and will only vest upon reaching the price target.

The entire senior management team, consisting of six individuals, voluntarily chose this performance-based structure over the traditional time-based vesting, demonstrating their confidence in the company's growth potential. Regular employees will continue with time-based vesting options. CEO Ilan Danieli expressed confidence that the share price target could be achieved in less than four years, while Chairman Richard Sandberg noted that this structure applies to leadership members most capable of impacting company performance.

Precipio (NASDAQ: PRPO), a specialty cancer diagnostics company, announces its Q3-2024 shareholder update conference call scheduled for November 18, 2024, at 5:00 PM EST. The call will discuss the company's Q3-2024 10-Q filing and provide financial highlights and analysis of core businesses. Shareholders can access the call via phone (844-695-5519 for domestic, 1-412-902-6760 for international) or pre-register online. Questions can be submitted in advance via email to investors@precipiodx.com. A replay will be available on Precipio's website approximately 24 hours after the call.

Precipio, Inc. (NASDAQ: PRPO) has launched an enhanced version of its Bloodhound MPN (Myeloproliferative Neoplasm) panel that can now differentiate between CALR type 1 and type 2 mutations. This advancement aligns with the latest National Comprehensive Cancer Network (NCCN) guidelines released in August 2024. The new panel is the only quantitative PCR-based panel on the market that distinguishes between CALR types alongside other relevant genes for MPN evaluation.

The inclusion of CALR mutation subtyping is significant for MPN patient care, as it can influence treatment strategies and outcomes. CALR gene mutations are prevalent in various myeloproliferative neoplasms and play a critical role in disease prognosis and therapeutic decision-making. The distinction between CALR types can indicate disease progression severity and inform physicians on specific treatment needs.

Precipio (NASDAQ: PRPO) announces the repricing of a portion of its employee stock options to enhance retention in the competitive cancer diagnostics industry. The company is repricing only options granted before 2023, representing 58% of outstanding options, from a weighted average strike price of $57.22 to $6.56. This change affects primarily already vested options (88%) and includes a one-year lock-in period. Management emphasizes that this decision aims to create shareholder value by retaining valuable employees without impacting cash or revenue. The repricing is expected to realign incentives and motivate employees to contribute to the company's success, ultimately benefiting shareholders through potential share price appreciation.

Precipio, Inc. (NASDAQ: PRPO), a specialty cancer diagnostics company, has announced its Q2-2024 shareholder update call scheduled for August 19, 2024, at 5:00 PM EDT. The conference call will provide updates on the company's core businesses and can be accessed by calling 844-695-5519 (or 1-412-902-6760 for international callers).

Participants can pre-register for the call at a provided link to receive a calendar invite and direct dial-in number. Shareholders can submit questions in advance via email to investors@precipiodx.com. A replay of the call will be available approximately 24 hours after the event on Precipio's website investor page.

Precipio, Inc. (NASDAQ: PRPO), a specialty cancer diagnostics company, has reported $0.3M cash generated by operations (unaudited) in Q2-2024. This positive cash flow marks a significant milestone as the company advances towards breakeven. With cash reserves of approximately $1.3M at the end of Q2-2024 and a promising business pipeline, management is optimistic about reaching breakeven by year-end.

CEO Ilan Danieli expressed satisfaction with the company's progress, highlighting the transition away from structured deals that may harm shareholders. The improved cash position alleviates the need for capital raises in the foreseeable future, allowing Precipio to focus on building a strong base of long-term healthcare shareholders.

Precipio Inc (NASDAQ: PRPO) reported unaudited Q2-2024 revenues of $4.4M, marking a 30% increase from Q1-2024's $3.4M. The company's Pathology Division reached its breakeven point in June, with anticipated growth to $1.5 million per month by year-end. The Products Division is onboarding three key accounts with full HemeScreen assay portfolios, expected to push the division past its breakeven threshold. Two accounts are projected to go live in Q3-2024, with the third following in Q4-2024. CEO Ilan Danieli expressed optimism about the company's progress towards profitability in 2024, citing growing customer demand for their offerings in both divisions.